Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
- PMID: 37287109
- PMCID: PMC10442140
- DOI: 10.1097/TP.0000000000004634
Outcomes With Belatacept Exposure During Pregnancy in Kidney Transplant Recipients: A Case Series
Abstract
Background: Posttransplant fertility returns quickly, and female recipients of child-bearing age may conceive while on immunosuppression. However, pregnancy after transplantation confers risks to the recipient, transplant, and fetus, including gestational hypertension, preeclampsia, gestational diabetes, transplant dysfunction, preterm labor, and low birthweight infants. Additionally, mycophenolic acid (MPA) products are teratogenic. Literature evidence regarding belatacept, a selective T-cell costimulation blocker, during pregnancy and while breastfeeding is extremely limited. When female transplant recipients on a belatacept-based regimen are desirous of pregnancy or at the time of conception, transplant providers manage the immunosuppression regimen in 1 of 2 ways: (1) switch both belatacept and MPA to a calcineurin inhibitor-based regimen with or without azathioprine, which is the more common practice but requires several modifications, having potential negative outcomes; or (2) only switch MPA to azathioprine while continuing belatacept.
Methods: This case series includes 16 pregnancies in 12 recipients with exposure to belatacept throughout pregnancy and while breastfeeding. Patient information was obtained from several sources, including Transplant Pregnancy Registry International, providers at Emory University, and Columbia University, as well as literature review.
Results: Pregnancy outcomes included 13 live births and 3 miscarriages. No birth defects or fetal deaths were reported in any of the live births. Seven infants were breastfed while their mothers continued belatacept. Outcomes appear comparable to those documented with the administration of calcineurin inhibitors.
Conclusions: This case series provides data supporting the continued administration of belatacept during pregnancy. Additional research will assist in developing better guidelines to counsel female transplant recipients on belatacept desiring to pursue pregnancy.
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Use of belatacept in kidney transplantation: what's new?Curr Opin Organ Transplant. 2023 Feb 1;28(1):36-45. doi: 10.1097/MOT.0000000000001033. Epub 2022 Nov 3. Curr Opin Organ Transplant. 2023. PMID: 36326538 Review.
-
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.J Am Soc Nephrol. 2021 Dec 1;32(12):3252-3264. doi: 10.1681/ASN.2021050628. Epub 2021 Dec 1. J Am Soc Nephrol. 2021. PMID: 34706967 Free PMC article. Clinical Trial.
-
Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.Transplantation. 2020 Jul;104(7):1500-1507. doi: 10.1097/TP.0000000000002976. Transplantation. 2020. PMID: 31568398
-
Immunosuppression and Reproductive Health After Kidney Transplantation.Transplantation. 2019 Nov;103(11):e325-e333. doi: 10.1097/TP.0000000000002903. Transplantation. 2019. PMID: 31397802 Review.
-
Belatacept during pregnancy in renal transplant recipients: Two case reports.Am J Transplant. 2018 Aug;18(8):2079-2082. doi: 10.1111/ajt.14911. Epub 2018 Jun 3. Am J Transplant. 2018. PMID: 29719109
References
-
- Transplant Pregnancy Registry International (TPRI) 2020 Annual Report, Gift of Life Institute, Philadelphia, PA 2021.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical